News
CLDX
30.65
-1.89%
-0.59
Celldex Therapeutics Price Target Raised to $68.00/Share From $60.00 by Canaccord Genuity
Dow Jones · 1d ago
Celldex Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 1d ago
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68
Benzinga · 1d ago
Celldex Therapeutics Price Target Raised to $61.00/Share From $57.00 by Morgan Stanley
Dow Jones · 1d ago
Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61
Benzinga · 1d ago
Guggenheim Keeps Their Buy Rating on Celldex (CLDX)
TipRanks · 1d ago
Celldex price target raised to $68 from $60 at Canaccord
TipRanks · 1d ago
Weekly Report: what happened at CLDX last week (1102-1106)?
Weekly Report · 1d ago
Why Celldex Therapeutics (CLDX) Is Up 5.7% And What's Next
Simply Wall St · 3d ago
Based on the search results, I can see that:
Barchart · 4d ago
Goldman Sachs Remains a Hold on Celldex (CLDX)
TipRanks · 4d ago
Cantor Fitzgerald Remains a Buy on Celldex (CLDX)
TipRanks · 4d ago
Is Celldex Therapeutics (CLDX) Undervalued On Its Latest Earnings Report?
Simply Wall St · 4d ago
Celldex Therapeutics Reports Third Quarter 2026 Financial Results
NASDAQ · 4d ago
Celldex Therapeutics Announces Filing Of Mixed Shelf Offering, Size Undisclosed
Benzinga · 5d ago
Celldex files automatic mixed securities shelf
TipRanks · 5d ago
Celldex GAAP EPS of -$0.96 beats by $0.07
Seeking Alpha · 5d ago
*Celldex Therapeutics 3Q Loss/Shr 96c >CLDX
Dow Jones · 5d ago
*Celldex Therapeutics 3Q Loss $75.6M >CLDX
Dow Jones · 5d ago
More
Webull provides a variety of real-time CLDX stock news. You can receive the latest news about Celldex Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.